Quick Answer
Fulcrum Therapeutics, Inc. reported Total Assets of $366.28 million for the year ending 2025.
- Fulcrum Therapeutics, Inc. showed an increase of +40.5% in Total Assets from 2024 to 2025.
- This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $65.15 million | Q3 2019: $115.96 million | Q1 2020: $94.86 million | Q2 2020: $144.86 million | Q3 2020: $142.22 million | Q1 2021: $156.48 million | Q2 2021: $137.88 million | Q3 2021: $255.55 million | Q1 2022: $220.25 million | Q2 2022: $195.23 million | Q3 2022: $247.81 million | Q1 2023: $321.12 million | Q2 2023: $300.33 million | Q3 2023: $278.88 million | Q1 2024: $232.59 million | Q2 2024: $294.26 million | Q3 2024: $279.01 million | Q1 2025: $242.65 million | Q2 2025: $228.84 million | Q3 2025: $214.86 million.
- Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Total Assets has grown by 327.0%.
- Historical annual values: Fiscal year 2025: $366.28 million | Fiscal year 2024: $260.72 million | Fiscal year 2023: $257.69 million | Fiscal year 2022: $226.69 million | Fiscal year 2021: $235.00 million | Fiscal year 2020: $129.58 million | Fiscal year 2019: $110.44 million | Fiscal year 2018: $85.77 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: